title: Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.
abstract: KS Biomedix (formerly Avicenna Medica; now a subsidiary of the Xenova group) and Nycomed, together with Japanese licensee Sosei and Chinese licensee PharmaEngine, are developing TransMID, a transferrin-mediated diphtheria toxin delivery system for the potential treatment of adult, recurrent, inoperable, high-grade glioma (as TransMID-107R). It is also under investigation for other forms of brain cancer, including early brain cancer (as TransMID-107N), metastatic brain cancer (as TransMID-107M) and pediatric brain cancer (as TransMID-107P). TransMID is currently undergoing phase III clinical trials.
authors.affiliation: The University of Liverpool, Division of Neuroscience, The Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK. N.G.Rainov@liverpool.ac.uk
authors.forename: Nikolai G
authors.initials: NG
authors.lastname: Rainov
authors.forename: Ariane
authors.initials: A
authors.lastname: Söling
mesh_terms: D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D004167:Diphtheria Toxin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents; C058384:CRM 107; D004167:Diphtheria Toxin